PD1 and PDL-1 expression during progression from myelodysplastic syndrome to acute myelogenous leukemia
US11287428B2 · kind B2 · utility
0Cited by
1References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 16, 2017 |
| Grant date | Mar 29, 2022 |
| Priority date | — |
| Expiry date | Jan 10, 2039 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/7028
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to a method for diagnosing in a subject the progression from myelodysplastic syndrome (MDS) to acute myelogenous leukemia (AML). Also disclosed are methods of treating AML in a subject diagnosed by the disclosed methods.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.